Since some of the DNA damaging agents were recently shown to be effective against GISTs cells in vitro and in vivo [22,23,24], we examined whether these drugs provide effective cytotoxic activities against the IM-resistant GIST T-1 subline lacking secondary KIT mutations and harboring the RTK switch. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.